Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...
Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results